HOME >> BIOLOGY >> NEWS
Gene therapy for chicken model of childhood blindness

In this week's PLoS Medicine Susan Semple-Rowland and colleagues, from the University of Florida, report the results of gene therapy for a chicken model of Leber congenital amaurosis (LCA), one of a group of hereditary diseases that cause blindness in infants and children.

Leber congenital amaurosis (LCA) is the name of a group of hereditary diseases that cause blindness in infants and children. Changes in any one of a number of different genes can cause the blindness, which usually comes on quite soon after birth. About 20% of children with LCA have the most common type called LCA1 which is caused by defects in a gene called retinal guanylate cyclase (GUCY2D). Defects in the gene leave the light sensitive photoreceptors in the eye unable to respond to light, and so cause blindness. Loss of function of these receptor cells leads to their degeneration and eventually breakdown of the retina the light sensitive tissue at the back of the eye.

There is an animal model of LCA1, a strain of chickens with a mutation in the chicken GUCY2D gene. These chickens develop a disease very similar to that of humans. Gene therapy works by replacing a defective gene with a normal functional one, usually by packaging the normal gene into a harmless virus and injecting it into the affected area, in this case the eye.

The researchers injected a virus containing the normal gene into chicken embryos that had the abnormal gene, and allowed the chicks to hatch normally. Of seven treated chicks, six appeared to develop sight, in contrast to untreated animals. The improvement in the chicks' sight occurred despite the fact that only a relatively small percentage of the receptor cells were infected by the virus.

This study shows that in theory it is possible to treat this form of childhood blindness by gene therapy. However, before clinical trials can be considered for humans, researchers would need to demonstrate that the virus is safe in humans, and addition
'"/>

Contact: Andrew Hyde
ahyde@plos.org
44-012-234-63330
Public Library of Science
22-May-2006


Page: 1 2

Related biology news :

1. Testosterone replacement therapy: How safe for aging men?
2. Progesterone therapy and preterm birth: More evidence helps identify women who can benefit
3. Aggressive therapy best for certain AML patients
4. Under magnetic force, nanoparticles may deliver gene therapy
5. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
6. Stem cell therapy rescues motor neurons in ALS model
7. Study identifies new gene therapy tools for inherited blindness
8. Breast cancer and hormone therapy -- A looking-glass mirror?
9. Radiation therapy combined with microsurgery shows promise for curing injured spinal cord
10. Nodal status is best predictor of outcome after neoadjuvant therapy for esophageal cancer
11. Scientists follow familiar TRAIL to new cancer therapy

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/7/2018)... BOSTON and SOUTH JORDAN, Utah (PRWEB) , ... August 07, 2018 ... ... communications and collaboration solutions, announced today their new CT Cloud Voice and SIP solutions. ... cloud delivering a scalable and secure, quality voice solution that is far superior to ...
(Date:8/2/2018)... (PRWEB) , ... August 02, 2018 , ... ... management solutions to pharmaceutical and biotech companies, today announced that Mark Jara, principal ... most inspiring people in the life sciences industry. Individuals named to PharmaVOICE 100 ...
(Date:8/1/2018)... ... July 31, 2018 , ... ... Awards at Global Conference , Awards honor late founder of Wisdom National Brands® ... National Brands, presented prestigious stevia awards to a renowned German professor and a ...
Breaking Biology News(10 mins):
(Date:7/25/2018)... ... July 25, 2018 , ... ... Foot Center of New York’s (FCNY) acquisition of several Erchonia low-level lasers, including ... podiatric medical education and clinical experience. Their students receive comprehensive academic training ...
(Date:7/24/2018)... ... July 24, 2018 , ... R3 Stem Cell is now ... The treatments are offered by Double Board Certified providers, with outcomes significantly improving patient ... suppressing symptoms, but have done nothing to help repair and regenerate damaged lung tissues. ...
(Date:7/22/2018)... ... July 19, 2018 , ... Mitotech S.A, ... Essex Bio-Investment for Phase 3 clinical program in Dry Eye Disease. Under the ... with approximately $17m allocated towards the first Phase 3 study starting as early ...
(Date:10/13/2017)... KING OF PRUSSIA, PA (PRWEB) , ... October 13, 2017 , ... ... Group Vice President and Turesol Business Unit Leader, will moderate a discussion on the ... this year’s ISPE Annual Meeting & Expo . The theme of this year’s ...
Breaking Biology Technology:
Cached News: